Effects of adding a leukotriene antagonist or a long-acting beta2- agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype

American Journal of Medicine

Volumn 109, Issue 2, 2000, Pages 114-121

  Lipworth, Brian J ^a   Dempsey, Owen J ^a   Aziz, Imran ^a   Wilson, Andrew M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; GLYCINE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METHACHOLINE; NITRIC OXIDE; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DEVICE; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; LIVER PROTECTION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; GLUCOCORTICOIDS; GLYCINE; HOMOZYGOTE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; NITRIC OXIDE; PLACEBOS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; TOSYL COMPOUNDS;

EID: 0034253942     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00454-X     Document Type: Article

References (38)

1. National Asthma Education, and Prevention Program. Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, Publication 97-4051; 1997.
2. Greening A.P., Ind P.W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 344:1994;219-224.
3. Woolcock A., Lundback B., Ringdal N., Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 153:1996;1481-1488.
4. Pauwels R., Lofdahl C.G., Postma D., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. NEJM. 337:1997;1405-1411.
5. Van Noord J.A., Schrereus A.J.M., Mol S.J.M., Mulder P.G.H. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 54:1999;207-209.
6. Lipworth B.J. Airway subsensitivity with long-acting beta 2-agonists is there cause for concern? Drug Safety. 16:1997;295-308.
7. Green S.A., Turki J., Vegarno P., et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airways smooth muscle cells. Am J Respir Cell Mol Biol. 13:1995;25-33.
8. Dewar J., Wilkinson J., Wheatley A., et al. The glutamine 27 beta 2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol. 100:1997;261-265.
9. Tan K.S., Hall I.P., Dewar J., et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:1997;995-999.
10. Lipworth B.J., Hall I.P., Aziz I., et al. Beta 2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short and long-acting beta 2-agonist therapy. Clin Sci. 96:1999;253-259.
11. Lipworth B.J. Leukotriene-receptor antagonists. Lancet. 353:1999;57-62.
12. Busse W., Nelson H., Wolf J., et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 103:1999;1075-1080.
13. 2-adrenoceptor agonists?: interactions in human contracted bronchi. Eur Respir J. 11:1999;583-588.
14. 2-adrenoceptor agonists with higher efficacy on guinea pig trachea and human bronchus in vitro. Br J Pharmacol. 113:1994;676-692.
15. Standards for diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 136:1997;225-244.
16. Standardisation of spirometry - update. Am Rev Respir Dis. 136:1987;1285-1298.
17. Beach J.R., Jung C.L., Avery H.A., et al. Measurement of airway responsiveness to methacholine relative importance of the precision of drug delivery and the method of assessing response. Thorax. 418:1993;239-243.
18. Kharitonov S.A., Chung K.F., Evans D.J., et al. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med. 153:1996;1773-1780.
19. Leff J.A., Busse W.W., Pullman D., et al. Montelukast, a leukotriene receptor antagonist for the treatment of mild asthma, and exercise induced bronchoconstriction. NEJM. 339:1998;147-152.
20. Westbroek J, Pasma HR. The effect of inhaled fluticasone propionate 100μg bd compared with oral zafirlukast 20mg bd on bronchial hyperresponsiveness in mild to moderate asthmatics. Eur Respir J. 1997;19(suppl 25):248S.
21. Rosenthal R., Lavins B.J., Hanby L.A. Effective treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild to moderate asthma. J Allergy Clin Immunol. 97:1996;250.
22. Fujimura M., Sakamoto S., Kamio Y., Matsuda T. Effect of a leukotriene-antagonist, ONO-0178, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 87:1993;133-138.
23. Nakamura Y., Hoshino M., Simm J.J., et al. Effect of the leukotriene-antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax. S3:1998;835-841.
24. Pizzichini E., Leff J.A., Reiss T.F., et al. Montelukast reduces airway eosinophilic inflammation in asthma a randomised controlled trial. Eur Respir J. 14:1999;12-18.
25. Kraan J., Coeter G.H., Van der Mark T.W., et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis. 137:1988;44-48.
26. Wilson A.M., Lipworth B.J. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild to moderate asthma. Am J Med. 108:2000;269-275.
27. Jatakanon A., Lim S., Kharitonov S.A., Barnes P.J. Correlation between exhaled nitric oxide, sputum eosinophils and methacholine responsiveness in patients with mild asthma. Thorax. 53:1998;91-95.
28. Lim S., Jatakanon A., John M., et al. Effects of inhaled budesonide on lung function and airway inflammation. Am J Resp Crit Care Med. 159:1999;22-30.
29. Sont J., Willens L.N.A., Bell E.H., et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long term treatment. Am J Respir Crit Care Med. 159:1999;1043-1061.
30. Dinh-Xuan A.T., Texereau J. Measuring exhaled nitric oxide not only a matter of how, but also why should we do it? Eur Respir J. 12:1998;1005-1007.
31. Bisgaard H., Loland L., Anhoj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med. 160:1999;1227-1231.
32. Dempsey OJ, Wilson AM, Sims EJ, Lipworth BJ. A comparison of once daily topical budesonide (BUD) and oral montelukast (MON) in seasonal allergic rhinitis (SAR) and asthma. Eur Respir J. 1999;14(suppl 30):530S.
33. Jatakanon A., Kharitonov S.A., Lim S., Barnes P.J. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 54:1999;108-114.
34. Lipworth B.J., Aziz I., Wilson A.M. Effects of formoterol and budesonide alone or combined on adenosine monophosphate challenge and exhaled nitric oxide. J Allergy Clin Immunol. 103:1999;S60.
35. Wallin A., Sandstrom T., Soderberg M., et al. The effects of regular inhaled formoterol, budesonide and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med. 158:1998;79-86.
36. Newnham D.M., Grove A., McDevitt D.G., Lipworth B.J. Subsensitivity of bronchodilator and systemic beta 2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax. 50:1995;497-504.
37. Aziz I., Tan K.S., Hall I.P., et al. Subsensitivity to bronchoprotection against adenosine monophosphate (AMP) challenge following regular once daily formoterol. Eur Respir J. 12:1998;580-584.
38. Lipworth B., Tan S., Devlin M., et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med. 104:1998;431-438.